Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonapanitase in Peripheral Artery Disease
NCT02953496Phase 1Withdrawn
- Sponsor
- Proteon Therapeutics
- Primary completion
- Apr 2019
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vonapanitase in peripheral artery disease (PAD), sponsored by Proteon Therapeutics. Primary endpoints: Incidence of adverse events at 6 months and Technical success of percutaneous injection. Status: withdrawn.
02
Drugs
vonapanitase
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02953496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953496.